検索ワード: trombocytæmi (デンマーク語 - 英語)

trombocytæmi
neutropaenia

ris purpura, trombocytæmi, trombocytabnormitet,
uncommon: anaemia

ikke almindelig: trombocytæmi, leukocytose.
uncommon: thrombocythaemia, leukocytosis.

trombocytæmi (inkl. forhøjet trombocyttal)a
thrombocythemia (incl. platelet count increased)a

desuden er der rapporteret trombocytæmi over normalområdet.
in addition, thrombocythaemia above the normal range has been reported.

leukopeni anæmi neutropeni leukocytose trombocytopeni trombocytæmi
leukopenia anaemia neutropenia leukocytosis thrombocytopenia thrombocytaemia

anæmi1, trombocytopeni3, trombocytæmi, eosinofili1, leukocytose2, lymfocytose
anaemia1, thrombocytopenia3, thrombocythemia, eosinophilia1, leukocytosis2, lymphocytosis

derfor anvendes det til behandling af patienter med essentiel trombocytæmi.
for this reason it is used to treat patients with essential thrombocythaemia.

hæmatom) , trombocytopeni, purpura, trombocytæmi, trombocytabnormitet, koagulationsforstyrrelse er
thrombocytopenia, purpura, thrombocythaemia, platelet abnormal, coagulation disorder

essentiel trombocytæmi er en sygdom, hvor knoglemarven producerer for mange blodplader.
essential thrombocythaemia is a disease in which the bone marrow produces too many platelets.

hos patienter med essentiel trombocytæmi blev komplet respons defineret som et fald i blodpladetallet til
in patients with essential thrombocythaemia complete response was defined as a decrease in platelet count to  600 x 109/l or a

behandling med xagrid bør kun iværksættes af en læge med kendskab til behandling af essentiel trombocytæmi.
treatment with xagrid should only be started by a doctor who has experience in the treatment of essential thrombocythaemia.

behandling med xagrid kapsler skal startes af en kliniker med erfaringer i styring af essentiel trombocytæmi.
treatment with xagrid capsules should be initiated by a clinician with experience in the management of essential thrombocythaemia.

essentiel trombocytæmi (et) er en sygdom, hvor knoglemarven producerer for mange blodplader.
essential thrombocythaemia (et) is a disease where the bone marrow produces too many platelets.

udvalget fandt, at fordelene ved xagrid opvejer risiciene som andetvalgsbehandling af udsatte patienter med essentiel trombocytæmi.
they decided that xagrid’ s benefits are greater than its risks as second-line treatment in at risk patients with essential thrombocythaemia.

trombocytæmi (herunder øget trombocyttal) synkope (herunder bevidsthedstab), svimmelhed, hovedpine
nausea

essentiel trombocytæmi er en tilstand, der optræder, når knoglemarven producerer for mange af de blodceller, der kaldes blodplader.
essential thrombocythaemia is a condition which occurs when the bone marrow produces too many of the blood cells known as platelets.

da essentiel trombocytæmi er sjælden, blev xagrid udpeget som "lægemiddel til sjældne sygdomme" den 29. december 2000.
because the number of people with essential thrombocythaemia is low, the disease is rare, and xagrid was designated as an ‘ orphan medicine’ (a medicine used in rare disease) on 29 december 2000.

diagnostiske retningslinjer for essentiel trombocytæmi bør følges nøje, og ved usikkerhed bør diagnosen revurderes regelmæssigt med bestræbelser på at differentiere mellem hereditær og sekundær trombocytose, hvilket kan omfatte genetisk analyse og knoglemarvsbiopsi.
diagnostic guidelines for essential thrombocythemia should be followed carefully and diagnosis reassessed periodically in cases of uncertainty, with effort made to distinguish from hereditary or secondary thrombocytosis, which may include genetic analysis and bone marrow biopsy.

ved de doser, der anbefales til brug ved behandling af essentiel trombocytæmi, kan anagrelid forstærke virkningen af andre lægemidler, der hæmmer eller modificerertrombocytfunktionen, f.eks. acetylsalicylsyre.
at the doses recommended for use in the treatment of essential thrombocythaemia, anagrelide may potentiate the effects of other medicinal products that inhibit or modify platelet function e.g. acetylsalicylic acid.